Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(4.15)
# 398
Out of 4,479 analysts
76
Total ratings
45.16%
Success rate
16.47%
Average return
Main Sectors:
18 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $10.56 | +42.05% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $1.74 | +359.77% | 7 | Mar 11, 2024 | |
| ACAD ACADIA Pharmaceuticals | Downgrades: Hold | $25 | $15.84 | +57.83% | 15 | Dec 14, 2023 | |
| IMVT Immunovant | Initiates: Buy | $50 | $26.52 | +88.54% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $137.49 | -1.08% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $5.96 | +168.46% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $20.39 | +204.07% | 5 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $4.34 | +176.50% | 6 | Dec 12, 2023 | |
| SAGE Sage Therapeutics | Initiates: Hold | $21 | $10.82 | +94.09% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $154.20 | -29.31% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $2.27 | +252.42% | 1 | Dec 12, 2023 | |
| LBPH Longboard Pharmaceuticals | Maintains: Buy | $24 → $17 | $30.74 | -44.70% | 3 | Mar 9, 2023 | |
| ATAI Atai Life Sciences | Maintains: Buy | $20 → $10 | $1.30 | +669.23% | 4 | Jan 9, 2023 | |
| PASG Passage Bio | Maintains: Buy | $7 → $5 | $1.00 | +400.20% | 2 | Nov 11, 2022 | |
| KOD Kodiak Sciences | Downgrades: Sell | $6 | $2.24 | +167.86% | 4 | Aug 2, 2022 | |
| DRTS Alpha Tau Medical | Initiates: Buy | $21 | $2.18 | +863.30% | 1 | Apr 4, 2022 | |
| INSM Insmed | Initiates: Outperform | n/a | $64.50 | - | 1 | Jul 11, 2017 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $23.94 | - | 1 | Jul 11, 2017 |
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $10.56
Upside: +42.05%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $1.74
Upside: +359.77%
ACADIA Pharmaceuticals
Dec 14, 2023
Downgrades: Hold
Price Target: $25
Current: $15.84
Upside: +57.83%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $26.52
Upside: +88.54%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $137.49
Upside: -1.08%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $5.96
Upside: +168.46%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $20.39
Upside: +204.07%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $4.34
Upside: +176.50%
Sage Therapeutics
Dec 12, 2023
Initiates: Hold
Price Target: $21
Current: $10.82
Upside: +94.09%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $154.20
Upside: -29.31%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $2.27
Upside: +252.42%
Longboard Pharmaceuticals
Mar 9, 2023
Maintains: Buy
Price Target: $24 → $17
Current: $30.74
Upside: -44.70%
Atai Life Sciences
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $1.30
Upside: +669.23%
Passage Bio
Nov 11, 2022
Maintains: Buy
Price Target: $7 → $5
Current: $1.00
Upside: +400.20%
Kodiak Sciences
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $2.24
Upside: +167.86%
Alpha Tau Medical
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $2.18
Upside: +863.30%
Insmed
Jul 11, 2017
Initiates: Outperform
Price Target: n/a
Current: $64.50
Upside: -
AnaptysBio
Jul 11, 2017
Initiates: Outperform
Price Target: n/a
Current: $23.94
Upside: -